Cargando…
Preparation, characterization and in-vivo efficacy study of glatiramer acetate (GA)-hydrogel-microparticles as novel drug delivery system for GA in RRMS
Relapsing Remitting Multiple Sclerosis is a chronic Central nervous system autoimmune disease. There is no absolute treatment for MS and the available remedies are called disease modifying therapies (DMTs). Glatiramer acetate (GA) is one of the FDA approved DMTs. Currently, injection-site problems a...
Autores principales: | Hadidi, Naghmeh, Pazuki, Gholamreza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772231/ https://www.ncbi.nlm.nih.gov/pubmed/36543898 http://dx.doi.org/10.1038/s41598-022-26640-x |
Ejemplares similares
-
Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study
por: Davis, Mat D., et al.
Publicado: (2017) -
Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018) -
The effect of glatiramer acetate, IFNβ-1a, fingolimod, and dimethyl fumarate on the expression of T-bet, IFN-γ, and MEG3 in PBMC of RRMS patients
por: Dabbaghi, Rozhin, et al.
Publicado: (2023) -
In Vitro Evaluation of DSPE-PEG (5000) Amine SWCNT Toxicity and Efficacy as a Novel Nanovector Candidate in Photothermal Therapy by Response Surface Methodology (RSM)
por: Hadidi, Naghmeh, et al.
Publicado: (2021) -
Design of double functionalized carbon nanotube for amphotericin B and genetic material delivery
por: Yazdani, Sara, et al.
Publicado: (2022)